skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Carmustine Sustained-Release Implant Wafer (Code C102847)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Carmustine Sustained-Release Implant Wafer

Definition: A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues.

Label: Carmustine Sustained-Release Implant Wafer

NCI Thesaurus Code: C102847 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL437131  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Carmustine Sustained-Release Implant Wafer

External Source Codes: 
PDQ Closed Trial Search ID 737196
PDQ Open Trial Search ID 737196 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C102847
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom